Biosimilar Trastuzumab EG12014 Matches Original Drug in Phase III Breast Cancer Trial
A Phase III trial of 807 patients found the trastuzumab biosimilar EG12014 statistically equivalent to reference trastuzumab in efficacy, safety, ...
A Phase III trial of 807 patients found the trastuzumab biosimilar EG12014 statistically equivalent to reference trastuzumab in efficacy, safety, ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine